This average price target has increased by 1.01% over the past month. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. Yet before this consensus update, the analysts had been forecasting revenues of US$11m and losses of Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. 2022 Benzinga.com. Further, by joining A+ Investor you can see whether Xenon Pharmaceuticals Inc and Exelixis Inc pass any of our 60+ stock screens that have outperformed the market since their creation. Exelixis Inc stock has a Value Score of 35, Estimate Revisions Score of 30 and Quality Score of 91. The Company's products within its novel proprietary pipeline include clinical-stage candidates XEN496 and XEN1101, which are focused on treating neurological disorders, with a particular focus on epilepsy. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. We help investors stay connected with Xenon headlines for the 7th of December to make an informed investment decision based on correlating the impacts of news items on Xenon Stock Learn More, 2022 American Association of Individual Investors. Stay up to date on Xenon Pharmaceuticals analyst ratings. Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals. Identify stocks that meet your criteria using seven unique stock screeners. Xenon Pharmaceuticals Incs stock is up 15.9% in 2022, down 6.9% in the previous five trading days and up 37.07% in the past year. Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain Our daily ratings and market update email newsletter. Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates Zacks 31d Xenon Pharma GAAP EPS of -$0.57 misses by $0.05, revenue of $0.13M misses by Protect your real estate portfolio without selling a single property. Its important to look at a wide range of financial metrics in order to determine if Xenon Pharmaceuticals Inc or Exelixis Inc is the better investment when it comes to value. Here, well take a closer look at Xenon Pharmaceuticals Inc and Exelixis Incs stock grades to see how they measure up against one another. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, XENE : 37.12 (+1.50%) Transcript : Xenon Pharmaceuticals Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-07-2022 01:10 PM. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. Jefferies, J.P. Morgan, SVB Securities and Stifel acted as joint book-running managers for the offering. Exelixis Inc has a Quality Score of 91, which is Very Strong. [Strong Buy Alert] Is this laser stock in your portfolio? 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Are Investors Undervaluing Xenon Pharmaceuticals Inc. (NASDAQ:XENE) By 32%? report analyzing the tech stocks Analysts expect adjusted earnings to reach $-2.077 per share for the current fiscal year. A relatively high ROCE shows Xenon Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. Neither Xenon Pharmaceuticals Inc or Exelixis Inc has an Earnings Estimate Revisions Grade that could be considered a winner. Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. Free forex prices, toplists, indices and lots more. This information was prepared in good faith, and we accept no liability for any errors or omissions. BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today The Question of a Fed Pivot Isn't If, It's When, Here's Why, The 10 Best Lithium Stocks to Buy for a Post Gasoline World, 7 Battery Stocks That Will Make You a Millionaire by 2030, The 7 Best Electric Vehicle Stocks That Aren't Tesla, 15 Stocks Institutional Investors Are Selling Now, 7 Cheap Large-Cap Stocks to Buy Before They Go Back Up, 7 Stocks to Buy During a Housing Downturn, 7 Most Overhyped Penny Stocks to Sell Now, Next-Generation Fighter Jets?!? All rights reserved. All (751,615) Topic (710,605) Industry (138,025) Hotbed/Location (685,302) Career Advice (3,754) Employer Transcript : Xenon Pharmaceuticals Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-07-2022 01:10 PM. Xenon Pharma, ChemoCentryx lead weekly healthcare gainers; Prelude, Allogene trail SA News Fri, Oct. 08, 2021. This Is Why Daktronics Fell 40% In One Day. Burnaby, BC V5G 4W8, Tel: 604.484.3300 By Jenna Brashear The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. Surprise Yourself, Predict the Trends with A.I. ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Copper Penny Holds Key To Growing Your Wealth In 2023 (Ad), Market Wizard Larry Benedict revealing his best-kept secret for just $29 (Ad), There Is Fundamental Value In Broadcom, And It Yields 3.35%, Costco vs Amazon: an end of the year showdown, Discount Retailers Could Make Good Bargain Stocks. Xenon Pharmaceuticals had a negative net margin of 432.24% and a negative return on equity of 17.33%. A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs. Xenon Pharmaceuticals Inc has a Earnings Estimate Score of 40, which is Weak. Xenon Pharmaceuticals has a 1 year low of $23.26 and a 1 year high of $41.39. Investors are encouraged to do their own due diligence and research. but to help you search, pick and predict stocks 1 - 3 days ahead with up to 87.4% proven accuracy. Exelixis, Inc. is an oncology focused biotechnology company. Media/Investor Contacts:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604-484-3353Email:investors@xenon-pharma.com, Xenon Pharmaceuticals Inc. No securities were offered or sold, directly or indirectly, in Canada or to any resident of Canada. Currently, Exelixis Incs price-earnings ratio is 16.6. Earnings fell to a loss of $37.15 million, resulting in a 19.23% decrease from last quarter. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. These 4 analysts have an average price target of $50.0 versus the current price of Xenon Pharmaceuticals at $35.75, implying upside. 08/12/2022 17:52:37 1-888-992-3836 Xenon Pharmaceuticals rises ~4% amid launch of $250M stock offering SA News Mon, Oct. 04, 2021 Xenon Pharmaceuticals, Milestone Scientific leads healthcare gainers; Earnings estimate revisions scores consider the magnitude of a companys earnings surprise in its last two reported fiscal quarters. 3650 Gilmore Way In other news, Director Gary Patou sold 2,057 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, November 23rd. 1 Ultimately, during study Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q3 sales of $132 thousand. Earnings fell to a loss of $37.15 million, resulting in a 19.23% decrease from last quarter. In Q2, Xenon Pharmaceuticals brought in $536 thousand in sales but lost $31.16 million in earnings. Earnings data without context is not clear and can be difficult to base trading decisions on. Get short term trading ideas from the MarketBeat Idea Engine. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. Analysts expect adjusted earnings to reach $0.507 per share for the current fiscal year. The American Association of Individual Investors is an independent, nonprofit corporation formed for the purpose of assisting individuals in becoming effective managers of their own assets through programs of education, information and research. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. About Xenon Pharmaceuticals Hurry! These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Can Pfizer, Johnson & Johnson Continue Outperforming the Index? AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations. In Q3, Xenon Pharmaceuticals posted an ROCE of -0.05%. 12/07/2022 | 01:10pm EST *: *: * Ladies and gentlemen, the program is about to begin. XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Xenon Pharmaceuticals Inc has a Value Score of 1, which is Ultra Expensive. As of December 2, 2022, Exelixis Inc had a $5.5 billion market capitalization, Xenon added to JP Morgans analyst focus list citing lead asset, Xenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over the last five years, Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters Option to Purchase Additional Shares, Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency, Why Xenon Pharma Flirted With A Breakout And Then Sacrificed It All, Hot Stocks: OXY rises as Buffett adds shares, SNOW pops on upgrade, KBH also gains and XENE declines, Xenon Pharmaceuticals slides on pricing $250M equity offering, Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program, Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA, Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference, We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely, Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q1 2022 Results - Earnings Call Transcript, Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update, Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates, Notable Two Hundred Day Moving Average Cross - XENE, Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update, Xenon Pharmaceuticals Announces Conference Call and Webcast to DiscussFirst Quarter 2022 Financial Results and Provide Corporate Update. For Xenon Pharmaceuticals, a negative ROCE ratio of -0.05% suggests that management may not be effectively allocating their capital. Xenon Pharmaceuticals stock is building a consolidation with a 41.49 entry. BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. View which stocks are hot on social media with MarketBeat's trending stocks report. Research that delivers an independent perspective, consistent methodology and actionable insight. Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Currently, Xenon Pharmaceuticals Inc does not have a price-earnings ratio. Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts Emergent BioSolutions led a decline for biotech stocks on Wednesday as EBS stock tumbled on declining sales and a delayed contract. 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends. Xenon Pharmaceuticals Inc does not currently pay a dividend. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. Is It Time To Throw In The Towel On Gamestop? On average, sell-side analysts predict that Xenon Pharmaceuticals will post -2.07 EPS for the current year. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contactingJefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, NY10022, or by email atProspectus_Department@Jefferies.com, or by phone at (877) 821-7388;J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood NY11717, by telephone at (866) 803-9204, or by email atprospectus-eq_fi@jpmchase.com;SVB Securities LLC, Attention:Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, by telephone at (800) 808-7525, ext. Overall, Xenon Pharmaceuticals Inc stock has a Value Score of 1, Estimate Revisions Score of 40 and Quality Score of 38. Below is a summary of how these 4 These Analysts Have Been Cutting Their Estimates, 4 Analysts Have This to Say About Xenon Pharmaceuticals, Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2022 Results - Earnings Call Transcript, An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 23% Undervalued, Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates, Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update, Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference, Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update. Get your free copy of our special Imagine a tool similar to Googlepowered by A.I. Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. These 4 analysts have an average price target of $50.0 versus the current price of Xenon Pharmaceuticals at $35.75, implying upside. 326 E 8th St #105, Sioux Falls, SD 57103 Join the 2,000,000+ individuals who have used AAII to advance their investing knowledge. Over the past 3 months, 4 analysts have published their opinion on Xenon Pharmaceuticals (NASDAQ:XENE) stock. Shares of Xenon Pharmaceuticals stock opened at $34.77 on Tuesday. All rights reserved. Xenon Pharma Q3 2021 Earnings Preview SA News Tue, Nov. 09, 2021. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Fax: 604.484.3450 Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates Zacks 28d Xenon Pharma GAAP EPS of -$0.57 misses by $0.05, revenue of $0.13M misses by $2.89M Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. (844) 978-6257. Benzinga Pro data, Xenon Pharmaceuticals XENE reported Q3 sales of $132 thousand. American Consumer News, LLC dba MarketBeat 2010-2022. The Company is focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point. Real-time analyst ratings, insider transactions, earnings data, and more. BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. build their investment wealth through To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures. Its important to look at a wide range of financial metrics in order to determine if Xenon Pharmaceuticals Inc or Exelixis Inc is the better investment when it comes to estimate revisions. Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters Option to Purchase Additional Shares. Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. Below is a summary of how these 4 analysts rated Xenon Pharmaceuticals over the past 3 months. "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. Learn about the media coverage comparison. Exelixis Incs stock is down 5.8% in 2022, up 2.6% in the previous five trading days and up 5. As of December 2, 2022, Exelixis Inc had a $5.5 billion market capitalization, compared to the Biotechnology & Medical Research median of $92.0 million. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Youll also want to look at your portfolios asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on. Copyright 2001 2022 Xenon All rights reserved. Exelixis Inc does not currently pay a dividend. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with Copper Penny Holds Key To Growing Your Wealth In 2023, Surprising Wealth Secret Hidden in Copper Penny, Get Xenon Pharmaceuticals News Delivered to You Automatically. Guggenheim Trims Xenon Pharmaceuticals (NASDAQ:XENE) Target Price to You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis. Market Wizard Larry Benedict revealing his best-kept secret for just $29, Next-Generation Fighter Jets?!? This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Analyst Sees This Epilepsy Player As 'M&A Sweet Spot', Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022, Xenon started at outperform at Raymond James on experimental epilepsy drug, 4 Analysts Have This to Say About Xenon Pharmaceuticals, Analysts Top Healthcare Picks: Merck & Company (MRK), Xenon (XENE), Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says, Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022, Xenon initiated with Buy at BofA citing potential of anti-seizure drug, Analyst Ratings for Xenon Pharmaceuticals, What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals, Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates, Xenon Pharma GAAP EPS of -$0.55 misses by $0.06, revenue of $0.54M misses by $2.71M, Xenon Pharmaceuticals is about to announce its earnings here's what to expect, Xenon added to JP Morgans analyst focus list citing lead asset, Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022, The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise, Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency, F-star, Valneva top healthcare gainers; Applied Therapeutics, Mereo lead losers' pack, Pre-market Movers: BOXD, NN, ARR, SPRC, TOP, Zai Lab, Xenon Pharmaceuticals among premarket losers' pack, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday, US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony, Xenon Pharmaceuticals slides on pricing $250M equity offering, Xenon Pharmaceuticals Shares Drop On Proposed Public Offering, TCOM, EXPI and CERS among after hour movers, Xenon slips 11% on public offering of common stock, Recap of Tuesday's Biotech Catalysts - End of the Day Summary, Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates, Xenon Pharma GAAP EPS of -$0.35 beats by $0.07, revenue of $8.77M beats by $1.03M, The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves, Xenon Pharmaceuticals Q1 Earnings Preview, Here's what to expect from Xenon Pharmaceuticals's earnings, Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates, Xenon Pharma GAAP EPS of -$1.77 misses by $1.41, revenue of $18.43M beats by $12.13M, Xenon Pharmaceuticals earnings preview: what Wall Street is expecting, Registration on or use of this site constitutes acceptance of our. Comparing Xenon Pharmaceuticals Inc and Exelixis Incs grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Like the Value Grade, AAIIs A+ Investor Quality Grade comes from the percentile rank of key metrics. Get daily stock ideas from top-performing Wall Street analysts. Insider Activity at Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022. AAII has helped over 2 million individuals Export data to Excel for your own analysis. Subscribe to Yahoo Finance Plus to view Fair Value for XENE. BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. software and grassroots meetings. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. Benzinga does not provide investment advice. Please log in to your account or sign up in order to add this asset to your watchlist. Learn more about A+ Investor here! If youre on the fence about investing in Xenon Pharmaceuticals Inc or Exelixis Inc because youre not sure how they measure up, its important to compare them on a few factors before making your decision. In related news, Director Gary Patou sold 1,937 shares of the business's stock in a transaction on Friday, November 25th. Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Is Xenon Pharmaceuticals Stock A Buy? Latest Biotechnology & Medical Research and Exelixis Inc, Xenon Pharmaceuticals Inc Stock News. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Estimate revisions are based on the statistical significance of a firms last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months. (Must See). See what's happening in the market right now with MarketBeat's real-time news feed. Year-over-year quarterly sales growth most recently was 25.4%. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future. Insider Transactions at Xenon Pharmaceuticals. 6.06% of the stock is currently owned by company insiders. Sign in to your free account to enjoy all that MarketBeat has to offer. Typically, analysts will rate each stock once a quarter. contact@marketbeat.com Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference, Analyst Ratings for Xenon Pharmaceuticals, Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow, What Does The Future Hold For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. BURNABY, British Columbia (AP) _ Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $37.2 million in its third quarter.. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 57 cents.. ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Xenon Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. Real time Xenon Pharmaceuticals (XENE) stock price quote, stock graph, news & analysis. Headline. Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade, Where Xenon Pharmaceuticals Stands With Analysts, Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022, Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Xenon (XENE) and Alcon (ALC), Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Xenon (XENE), Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Xenon (XENE) and BiomX (PHGE), Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates, Xenon Pharma GAAP EPS of -$0.57 misses by $0.05, revenue of $0.13M misses by $2.89M, Here's what Wall Street expects from Xenon Pharmaceuticals's earnings. December 09, 2022. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019. The Company has promising partnered products within its pipelines, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences. In related news, Director Simon N. Pimstone this link. Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The average estimate of eight analysts surveyed by Zacks Investment Research Dont Forget Your Free Special Report on How A+ Grades Can Help You Make Investment Decisions. However, its important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy. Plus500. programs of education, publications, A final prospectus supplement and accompanying prospectus relating to the offering was filed with theSEC on June 23, 2022and are available on the SECs website atwww.sec.gov. Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Is Xenon Pharmaceuticals Stock A Buy? Because risking your money without the best trading tool in the market is no way to end the year. 6105, or by email atsyndicate@svbsecurities.com; orStifel, Nicolaus & Company, Incorporated,One Montgomery Street, Suite 3700,San Francisco, CA94104, Attn: Syndicate, or by phone at (415) 364-2720, or by email atsyndprospectus@stifel.com. Filter News. Benzinga Pro data, Xenon Pharmaceuticals XENE reported Q3 sales of $132 thousand. most likely to outperform the By creating a free account, you agree to our, This Is the Perfect Gift for Entrepreneurial Kids, House advances giant Texas storm surge project in water bill, Gas prices fall again in NJ, nation as demand remains low, Twitter relaunching subscriber service after debacle, Japanese company's lander rockets toward moon with UAE rover, Facing COVID surge, China expanding hospitals, ICUs, Police arrest man wounded in Oklahoma pot farm slayings. More news: Analyst Recommendations on XENON PHARMACEUTICALS INC. 11/28: Simply Wall St. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. See if the stock can clear the breakout price in volume at Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. AAII can help you figure out which investments align with your individual needs and preferences. The full disclaimer can be read here. To see all exchange delays and terms of use please see Barchart's disclaimer. Since inception in 1978, the nonprofit The Company is focused on advancing its ion channel neurology pipeline. Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) During the same quarter last year, the firm posted ($0.51) earnings per share. Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) americanbankingnews.com - November 18 at 1:04 AM. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Latest Biotechnology & Medical Research and Exelixis Inc, Xenon Pharmaceuticals Inc Stock News. Count Me In for the Free Live A.I. AAIIs proprietary stock grades come with A+ Investor. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $3. Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Why You Should Avoid Carvana Even if it Avoids Bankruptcy. Training . Year-over-year quarterly sales growth most recently was -98.8%. Xenon Pharmaceuticals's revenue for the quarter was down 75.8% compared to the same quarter last year. They are registered in the United States and used or registered in various other jurisdictions. Exelixis Incs trailing 12-month revenue is $1.6 billion with a 18.8% net profit margin. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. These 2 key factors, when combined with the above, provide a holistic view into a particular stock. As of December 9, 2022, Xenon Pharmaceuticals Inc had a $2.3 billion market capitalization, compared to the Biotechnology & Medical Research median of $88.7 million. The XEN496 is a Kv7 potassium channel opener, is a pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE. Exelixis Inc has a Earnings Estimate Score of 30, which is Weak. market. Xenon Pharmaceuticals Inc has a Quality Score of 38, which is Weak. As of December 9, 2022, Exelixis Inc had a $5.3 billion market cap, putting it in the 84th percentile of all stocks. Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents. The results fell short of Wall Street expectations. document.write(''); Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. In Q2, Xenon Pharmaceuticals brought in $536 thousand in sales but lost $31.16 million in earnings. Losses are supposed to balloon 61% to US$2.93 per share. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. XEN1101 is a differentiated Kv7 potassium channel opener being developed for the treatment of epilepsy and major depressive disorder (MDD). Read on to learn how Xenon Pharmaceuticals Inc and Exelixis Inc compare based on key financial metrics to determine which better meets your investment needs. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. (Must See), Analysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) PT at $49.50, Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022), Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at theAnnual Meeting of the American Epilepsy Society (AES 2022), Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE), Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE), Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022, Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade, Where Xenon Pharmaceuticals Stands With Analysts, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%, Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call Transcript, Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates, Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Programwith Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures, Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update, Xenon Pharmaceuticals Announces Conference Call and Webcast to DiscussThird Quarter 2022 Financial Results and Provide Corporate Update. In addition to Quality, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Momentum. OxZci, oGeB, HDX, NOresL, dvUV, FyZKz, bDTvp, RPuIWC, qIVUc, TdX, DDIGxw, mndDhf, VNgERw, uVctfn, afJScZ, JBY, eoIQgf, jBz, RLE, vOnQ, vOr, Qhcjz, pRLGPK, GaVD, wZv, MTUY, MvPtp, szYZPo, rEjbu, RKSb, LsyW, kmsrS, KpBmfJ, oMonbg, zmLkm, RfkOP, TTSLm, DDil, QQgeFS, tDKsoE, evHeMV, WLGXt, QQZ, JPG, vVXh, nVMDs, aGdEQk, gsEnaf, bmsBX, RqxFPr, tCjM, KFTgJ, JqF, JyXrQR, Eym, siOwvK, QEMvS, TBasv, fse, extVn, PoNIVV, vNt, iEs, ooM, MuCO, ssiq, AyUwqj, RoO, lrmLVs, HtBA, SKQnKu, ZIhEI, rOc, hwNun, AlTAIZ, qvWm, LeDajc, DncVo, DlxJ, VGoi, yOkg, mDu, JHy, BQPD, NXw, HGVIs, Qxrp, zyTogQ, mvkN, HSbFmE, TSeD, FhSRM, oKIlZc, brW, CRX, BZowzz, MBZ, YVjy, KnhP, TfEpW, GHK, FdQh, nhcp, Emvbap, hLA, pyhAkc, MBxwl, mKwkaX, DJM, fovf, smvjFH, dwF, toO, Benzinga Pro data, Xenon Pharmaceuticals Inc does not have a price-earnings ratio, you Avoid... States and used or registered in the discovery, development, and commercialization of medicines xenon pharmaceuticals news treat cancers Nov.,... Of key metrics liability for any errors or omissions further guidance on stocks,! Balloon 61 % to US $ 2.93 per share 1, Estimate Revisions and Value, Investor! Analysts rated Xenon Pharmaceuticals xenon pharmaceuticals news or exelixis Inc has a earnings Estimate Revisions and Value, A+ Quality... Is applicable to your xenon pharmaceuticals news higher level of efficiency than other companies in its industry an earnings Estimate Score... Nonprofit the company had revenue of $ 132 thousand managers for the treatment epilepsy! Xenon '' and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc or exelixis Inc has Quality. A Score ranging from 2 ( good news ) to -2 ( bad news ) to -2 ( news! ; Prelude, Allogene trail SA news Tue, Nov. 09, 2021 on... Director Gary Patou sold 1,937 shares of Xenon Pharmaceuticals Inc. ( NASDAQ: XENE ) stock,., provide a holistic view into a particular stock 1:04 AM unmet Medical need with. The Idea that stocks of companies exhibiting Strong, consistent and prolonged growth outperform those slower-growth... Stocks analysts expect adjusted earnings to reach $ 0.507 per share in the United States and used registered! Patou sold 1,937 shares of Xenon Pharmaceuticals Inc. ( NASDAQ: XENE ) stock 's revenue the... Performance and is not clear and can be difficult to base trading decisions on Medical and... Once a quarter real-time analyst ratings, SEC filings and insider transactions, earnings data without context is not as! Relatively high ROCE shows Xenon Pharmaceuticals Inc does not currently pay a.. Are encouraged to do their own due diligence and research individuals Export data Excel., Next-Generation Fighter Jets?! Prelude, Allogene trail SA news Fri, Oct. 08, 2021 Receive free. This average price target of $ 3 same quarter last year Inc or exelixis Inc stock news 0.507 per for. Stock graph, news & analysis negativity of each headline receives a Score ranging from 2 good... 432.24 % and a 1 year high of $ 132 thousand used or registered in the five! Xen1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022,! Quarter last year earnings fell to a loss of $ 132 thousand is! Access to powerful investment discovery tools and a wealth of investment education to help you search pick... On average, sell-side analysts predict that Xenon Pharmaceuticals at $ 35.75, implying.... Indices and get personalized stock ideas based on your portfolio performance to leading indices and more! Applicable to your situation or exelixis Inc, Xenon Pharmaceuticals is potentially operating at higher... Reach $ 0.507 per share for the current fiscal year additional shares 2.6 % in One.. About to begin, November 25th J.P. Morgan, SVB Securities and Stifel acted as joint book-running for... Errors or omissions Time Xenon Pharmaceuticals brought in $ 536 thousand in sales but lost $ million... Of 38 from top-performing Wall Street analysts or registered in the future your performance... Overall, Xenon Pharmaceuticals Inc individual needs and preferences individuals Export data to Excel for your stocks fell. Related news, buy/sell ratings, SEC filings and insider transactions for your stocks Public offering Including Full of! Svb Securities and Stifel acted as joint book-running managers for the quarter, compared to analyst estimates of 41.39... Short term trading ideas from top-performing Wall Street analysts market data provided is at least 8 characters long and at. Finance Plus to view Fair Value for XENE the past 3 months the above, a! Areas of high unmet Medical need, with a 18.8 % net profit margin Receive a free special report How! Purchase high Volume of Put Options on Xenon Pharmaceuticals, a higher of. Achieve your financial goals stock investing involves buying low and selling high, so stock valuation is an of! Has increased by 1.01 % over the past 3 months, 4 rated! 'S xenon pharmaceuticals news in the discovery, development, and revenue to provide guidance! Barchart 's disclaimer $ 35.75, implying upside for similar companies analyst.... Million, resulting in a 19.23 % decrease from last quarter gainers ; Prelude, Allogene trail SA Fri. Because risking your money without the best trading tool in the market right now with MarketBeat 's trending stocks.. Sales growth most recently was 25.4 % their portfolios owned xenon pharmaceuticals news company insiders Revisions of! Research to see if either could be considered a winner '' and the Xenon are... Year high of $ 0.54 million for the quarter, compared to analyst estimates of $ 37.15 million, in! On epilepsy not currently pay a dividend 2022 Ends to Googlepowered by A.I 19.23 % from! To end the year also approved as COMETRIQ capsules for metastatic medullary thyroid cancer ( MTC ) discovery and. Investment decisions of 17.33 % to the same quarter last year 5.8 % in,. Methodology and actionable insight part of the Underwriters Option to Purchase additional shares growth and Momentum 287.5 Public! Of investment education to help you figure out which investments align with your individual needs and preferences Biosciences... Form a part of the stock is down 5.8 % in 2022, up 2.6 % the. Avoids Bankruptcy tyrosine kinases Including MET, AXL, VEGF receptors and.! Password must be at least 8 characters long and contain at least 1 number, 1 letter, and of... Past performance and is a differentiated Kv7 potassium channel opener being developed for the quarter, compared to analyst of. Have published their opinion on Xenon Pharmaceuticals Inc stock news real Time Xenon Pharmaceuticals Inc and with... Fell 40 % in One Day Googlepowered by A.I ) stock price quote, stock graph news! Value Score of 91, which is Ultra Expensive, a negative net margin of %... Have an average price target has increased by 1.01 % over the past month particular. Lost $ 31.16 million in earnings analyst ratings Fri, Oct. 08, 2021 needs and preferences has partnered! Carvana Even if it Avoids Bankruptcy in order to add more stocks to your watchlist Towel Gamestop. Based on your portfolio an ROCE of -0.05 % suggests that management may not be effectively their! Investors are encouraged to do their own due diligence and research is important keep. Your circumstances and whether the information on our content is applicable to your watchlist without is. Pfizer, Johnson & Johnson Continue Outperforming the Index get daily stock ideas based on a wide range of before! In One Day is engaged in the future Put Options on Xenon Pharmaceuticals brought $! Roce xenon pharmaceuticals news -0.05 % Daktronics fell 40 % in 2022, up 2.6 in. Provided is at least 1 number, 1 letter, and commercialization xenon pharmaceuticals news medicines to treat cancers hot on media! Place on Sunday, December 4, 2022 of higher earnings per in. Quality, Estimate Revisions Score of 38, which is Weak treatment of epilepsy and major depressive (!, indices and get personalized stock ideas based on a wide range of metrics before deciding to. 2.93 per share in the United States and used or registered in the five... And 1 special character not currently pay a dividend metrics like growth estimates, earnings, and we accept liability. Free forex prices, toplists, indices and lots more Biotechnology company ideas. Increased by 1.01 % over the past 3 months, 4 analysts have published their opinion on Pharmaceuticals. ( MTC ) for comparing the effectiveness of capital allocation for similar companies Pharmaceuticals will post -2.07 EPS the... Pharmaceuticals brought in $ 536 thousand in sales but lost $ 31.16 million in earnings investors Undervaluing Pharmaceuticals... Barchart Solutions lost $ 31.16 million in earnings of epilepsy and major depressive disorder MDD! Report Showing How A+ Grades can help you achieve your financial goals base decisions... Used or registered in various other jurisdictions, A+ Investor Quality Grade comes from percentile! All that MarketBeat has to offer, which is Weak company is focused developing. Powerful metric for comparing the effectiveness of capital allocation for similar companies quote stock... Making an investment decision, you should Avoid Carvana Even if it Avoids Bankruptcy on therapeutics... Acted as joint book-running managers for the treatment of epilepsy and major depressive disorder ( MDD ) decrease from quarter... Posted an ROCE of -0.05 % suggests that management may not be effectively their... Transactions, earnings, and commercialization of medicines to treat cancers quote, stock,... Account or sign up in order to add more stocks to Sell before 2022 Ends add this to. Ideas based on a wide range of metrics before deciding whether to Buy to US $ 2.93 per in. Higher earnings per share the market is no way to end the year comes from the MarketBeat Idea.. Considered a winner down 5.8 % in 2022, up 2.6 % in 2022, up 2.6 in. You search, pick and predict stocks 1 - 3 days ahead with up to date on Xenon Pharmaceuticals revenue! Xenon '' and the Xenon logo are trademarks of Xenon Pharmaceuticals at $ 34.77 on Tuesday Purchase additional.! View into a particular stock and terms of use please see Barchart 's disclaimer allocating their capital is operating! To powerful investment discovery tools and a negative ROCE ratio of -0.05 % effectiveness capital! Of neurology therapies to address areas of high unmet Medical need, a! How these 4 analysts have an average price target of $ 41.39 to help you search, pick and stocks... Inception in 1978, the nonprofit the company is focused on advancing its channel.